DRG Epidemiology’s coverage of osteopenia comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of osteopenia for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
DRG Epidemiology’s osteopenia forecast will answer the following questions:
Of all people with osteopenia, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
Of all people diagnosed with osteopenia, how many in each of the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of osteopenia over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following osteopenia patient populations:
Total Prevalence Estimates of Osteopenia per 1,000 People Aged 40+ in 2021 and 2031
Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Osteopenia over the Next Ten Years
Epidemiology Data
Methods
Total Prevalent Cases
Diagnosed and Drug-Treated Prevalent Cases
Reference Materials
Literature Review
Studies Included in the Analysis of Osteopenia
Studies Excluded from the Analysis of Osteopenia
Risk/Protective Factors
Risk/Protective Factors for Osteopenia
Bibliography
Abbreviations
Glossary
Surup Dey
Surup Dey, M.L.T., M.P.H., is an epidemiologist at Clarivate. Previously, he worked in the field of medical diagnostic microbiology and was involved in the diagnosis of rare hematological disorders. Mr. Dey has a background in medical laboratory science from Christian Medical College in Vellore and a postgraduate degree in public health specializing in epidemiology from Manipal University.
Swarali Tadwalkar
Swarali Tadwalkar, M.P.H., is a principal epidemiologist at Clarivate. Previously, she was involved in primary and secondary healthcare research, including projects in digital health, health policy and management, and health economics and outcomes research (HEOR). Ms. Tadwalkar also coordinated various nongovernmental public health projects focusing on access to treatment for hepatitis and human papilloma virus. She received her M.P.H. from the University of South Florida in Tampa.
